Sector News

Roche partners with Jnana on SLC transporters

July 23, 2020
Life sciences

Roche and Jnana Therapeutics have entered into a collaboration to discover new medicines targeting key regulators of cellular metabolism to treat immune-mediated and neurological diseases.

Jnana Therapeutics has announced a strategic, multi-target collaboration and license agreement with Roche for the discovery of small molecule drugs directed at the solute carrier (SLC) family of metabolite transporters, to treat immune-mediated and neurological diseases.

Under the terms of the deal, Jnana and Roche will work together on discovery and preclinical development for a broad set of targets across immunology and neuroscience – utilising the US biotech’s RAPID platform, designed to overcome the challenges of directly targeting SLC transporters – which Roche will then further develop and commercialise exclusively.

Jnana will receive an upfront payment of $40 million in cash, and could also bank research funding, preclinical, development and commercialisation milestone payments, as well as royalties, with the aggregate value of future payments to Jnana potentially exceeding $1 billion.

“We are delighted to partner with Roche to pursue the untapped potential of SLC transporters as a new approach to develop medicines in major disease areas with high unmet medical need,” said Joanne Kotz, co-founder, chief executive and president of Jnana.

“This collaboration with Roche will expand the impact of Jnana’s platform so that, together, we can broadly address compelling SLC targets and bring new treatments to patients with immune-mediated and neurological diseases.”

“We are excited about Jnana’s small molecule approach to targeting SLC transporters, which represent a promising class of targets for discovering new medicines for patients across a range of diseases,” added James Sabry, head of Roche Pharma Partnering.

SLC transporters are a class of more than 450 human membrane proteins that are gatekeepers for controlling the movement of metabolites in and out of cells and organs. They ensure that metabolites are present in the right place at the right time, which is crucial for health and often dysregulated in disease.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.